Bank of New York Mellon Corp Purchases New Position in Enliven Therapeutics, Inc. $ELVN

Bank of New York Mellon Corp acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 118,853 shares of the company's stock, valued at approximately $6,032,000. Bank of New York Mellon Corp owned approximately 0.20% of Enliven Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. KBC Group NV bought a new stake in Enliven Therapeutics during the first quarter worth $38,000. BNP Paribas Financial Markets lifted its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Enliven Therapeutics during the fourth quarter valued at about $83,000. Quantbot Technologies LP raised its holdings in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares during the period. Finally, State of Wyoming purchased a new stake in shares of Enliven Therapeutics during the second quarter worth $96,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company's stock, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of the company's stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the sale, the director owned 41,884 shares of the company's stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 186,849 shares of company stock valued at $10,998,857. Company insiders own 3.00% of the company's stock.

Enliven Therapeutics Stock Down 0.6%

Shares of NASDAQ:ELVN opened at $59.32 on Friday. The stock has a market capitalization of $4.35 billion, a P/E ratio of -35.52 and a beta of 0.30. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32. The firm has a fifty day simple moving average of $55.66 and a two-hundred day simple moving average of $44.19.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ELVN. Guggenheim decreased their price target on Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. JonesTrading increased their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Mizuho increased their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. Finally, The Goldman Sachs Group raised their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $75.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source